CVS Health has announced that it will prioritize the use of biosimilars over Johnson & Johnson's Stelara, an immunosuppressive drug, beginning in July. This decision is part of CVS's broader strategy to enhance cost-effectiveness and improve patient access to medications. The shift is expected to impact prescribing practices and may influence the availability of Stelara in CVS pharmacies. The move aligns with ongoing trends in the pharmaceutical industry towards the adoption of biosimilars.
Related Articles
Don't miss out on breaking stories and in-depth articles.